ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.
Metrics to compare | 298380 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship298380PeersSector | |
|---|---|---|---|---|
P/E Ratio | −238.4x | −33.1x | −0.5x | |
PEG Ratio | −6.38 | 0.01 | 0.00 | |
Price/Book | 58.3x | 2.5x | 2.6x | |
Price / LTM Sales | 113.6x | 26.6x | 3.2x | |
Upside (Analyst Target) | 46.3% | −9.7% | 47.4% | |
Fair Value Upside | Unlock | 0.6% | 7.7% | Unlock |